×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ONCT – oncternal therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ONCT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/19
03:02 am
onct
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/11
02:05 am
onct
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/3
02:07 am
onct
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
10/26
02:10 am
onct
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
10/22
09:00 am
onct
Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
High
Report
Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
10/18
02:06 am
onct
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
10/10
02:03 am
onct
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
10/2
02:03 am
onct
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
8/8/2024
04:01 pm
onct
oncternal therapeutics, inc.
BEAT
Report
-8.4%
oncternal therapeutics, inc.
5/9/2024
04:01 pm
onct
oncternal therapeutics, inc.
BEAT
Report
-5.3%
oncternal therapeutics, inc.
3/7/2024
04:01 pm
onct
oncternal therapeutics, inc.
MISS
Report
3.7%
oncternal therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
05:08 pm
onct
Form 8-K Oncternal Therapeutics, For: Nov 13
Low
Report
Form 8-K Oncternal Therapeutics, For: Nov 13
11/6
04:31 pm
onct
Form 10-Q Oncternal Therapeutics, For: Sep 30
High
Report
Form 10-Q Oncternal Therapeutics, For: Sep 30
10/15
12:12 pm
onct
Form 144 Oncternal Therapeutics, Filed by: Yazji Salim
Medium
Report
Form 144 Oncternal Therapeutics, Filed by: Yazji Salim
9/12
04:50 pm
onct
Form 8-K Oncternal Therapeutics, For: Sep 11
High
Report
Form 8-K Oncternal Therapeutics, For: Sep 11
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/10
Oncternal Therapeutics Completes Reverse Merger with GTx, Inc.
61.2%
10/11 Oncternal Should Be On Your Radar As Speculative Play Based On Recent Progress [Seeking Alpha] 31.5%
3/11 Oncternal Therapeutics Announces Interim Clinical Data Update, Including 50% Complete Response Rate, for Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma 12.2%
8/11 Oncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 11.1%
11/5 Oncternal Therapeutics Announces Interim Clinical Data on TK216 in Ewing Sarcoma to Be Presented at the CTOS 2019 Annual Meeting 8.8%
6/18 Form SC 13D Oncternal Therapeutics, Filed by: Shanghai Pharmaceutical (USA) Inc. 7.9%
12/23 Form 8-K Oncternal Therapeutics, For: Dec 23 7.5%
8/6 Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study of Cirmtuzumab in Combination with Ibrutinib 5.7%
11/11 Oncternal Therapeutics to Present at Stifel Healthcare Conference 5.7%
9/9 Form 4 Oncternal Therapeutics, For: Sep 05 Filed by: Kaufmann Gunnar F. 3.9%
10/11 Oncternal Should Be On Your Radar As Speculative Play Based On Recent Progress [Seeking Alpha] 31.5%
3/11 Oncternal Therapeutics Announces Interim Clinical Data Update, Including 50% Complete Response Rate, for Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma 12.2%
8/11 Oncternal Therapeutics, Inc. (ONCT) CEO James Breitmeyer on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 11.1%
11/5 Oncternal Therapeutics Announces Interim Clinical Data on TK216 in Ewing Sarcoma to Be Presented at the CTOS 2019 Annual Meeting 8.8%
6/18 Form SC 13D Oncternal Therapeutics, Filed by: Shanghai Pharmaceutical (USA) Inc. 7.9%
12/23 Form 8-K Oncternal Therapeutics, For: Dec 23 7.5%
8/6 Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study of Cirmtuzumab in Combination with Ibrutinib 5.7%
11/11 Oncternal Therapeutics to Present at Stifel Healthcare Conference 5.7%
9/9 Form 4 Oncternal Therapeutics, For: Sep 05 Filed by: Kaufmann Gunnar F. 3.9%
TOP News Decliners
3/11
Oncternal Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Business Update
-16.2%
6/11 Form 3 GTX INC /DE/ For: Jun 07 Filed by: HALE DAVID F -16.2%
8/9 Form 8-K/A Oncternal Therapeutics, For: Jun 07 -12.6%
12/9 Oncternal Therapeutics Announces Presentation of Clinical Data Update on Cirmtuzumab in Combination with Ibrutinib at 2019 ASH Annual Meeting -11.8%
4/2 Form 8-K Oncternal Therapeutics, For: Apr 02 -11.7%
3/18 Form 4 Oncternal Therapeutics, For: Mar 17 Filed by: VINCENT RICHARD G -10.8%
12/11 Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of TK216, Targeted ETS Inhibitor, in Patients with Ewing Sarcoma -10.6%
8/15 Form S-8 Oncternal Therapeutics, -9.8%
6/20 Form 4 Oncternal Therapeutics, For: Jun 18 Filed by: BREITMEYER JAMES B -9.2%
12/12 Oncternal Therapeutics Announces Presentation of Interim Clinical Data on Cirmtuzumab in Combination with Paclitaxel at 2019 San Antonio Breast Cancer Symposium -9.0%
6/11 Form 3 GTX INC /DE/ For: Jun 07 Filed by: HALE DAVID F -16.2%
8/9 Form 8-K/A Oncternal Therapeutics, For: Jun 07 -12.6%
12/9 Oncternal Therapeutics Announces Presentation of Clinical Data Update on Cirmtuzumab in Combination with Ibrutinib at 2019 ASH Annual Meeting -11.8%
4/2 Form 8-K Oncternal Therapeutics, For: Apr 02 -11.7%
3/18 Form 4 Oncternal Therapeutics, For: Mar 17 Filed by: VINCENT RICHARD G -10.8%
12/11 Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of TK216, Targeted ETS Inhibitor, in Patients with Ewing Sarcoma -10.6%
8/15 Form S-8 Oncternal Therapeutics, -9.8%
6/20 Form 4 Oncternal Therapeutics, For: Jun 18 Filed by: BREITMEYER JAMES B -9.2%
12/12 Oncternal Therapeutics Announces Presentation of Interim Clinical Data on Cirmtuzumab in Combination with Paclitaxel at 2019 San Antonio Breast Cancer Symposium -9.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: